CAJ | 학술논문

　　目的探讨腹膜假性黏液瘤的临床特点及术后并发症相关危险因素。方法收集我院2002-2011年收治的39例腹膜假黏液瘤患者的临床数据，回顾性分析术后并发症的发生情况和预后影响因素。结果39例中，17例出现术后并发症，并发症发生率为43%，主要并发症有腹腔内感染及肠梗阻。25例术后复发，中位复发时间12个月。美国东部肿瘤协作组(Eastem Cooperative Oncology Group，ECOG)评分≥1发生术后并发症的风险增加(P＜0.05)。性别、年龄、手术时间及术后是否行腹腔内热化疗对术后并发症发生风险无统计学意义。单因素及多因素分析显示病理分型为弥散性腹膜黏液腺瘤病及治疗方式为手术联合热化疗对推迟术后复发时间有统计学意义(P＜0.05)。结论对于ECOG评分≥1的患者应谨慎选择手术并应预防术后并发症的发生。病理分型为弥散性腹膜黏液腺瘤病的患者术后联合腹腔内热化疗可推迟术后复发时间。
　　목적탐토복막가성점액류적림상특점급술후병발증상관위험인소。방법수집아원2002-2011년수치적39례복막가점액류환자적림상수거，회고성분석술후병발증적발생정황화예후영향인소。결과39례중，17례출현술후병발증，병발증발생솔위43%，주요병발증유복강내감염급장경조。25례술후복발，중위복발시간12개월。미국동부종류협작조(Eastem Cooperative Oncology Group，ECOG)평분≥1발생술후병발증적풍험증가(P＜0.05)。성별、년령、수술시간급술후시부행복강내열화료대술후병발증발생풍험무통계학의의。단인소급다인소분석현시병리분형위미산성복막점액선류병급치료방식위수술연합열화료대추지술후복발시간유통계학의의(P＜0.05)。결론대우ECOG평분≥1적환자응근신선택수술병응예방술후병발증적발생。병리분형위미산성복막점액선류병적환자술후연합복강내열화료가추지술후복발시간。
Objective To study the clinical characteristics of peritoneal pseudomyxoma and the relative risk factors for its postoperative complications. Methods Thirty-nine peritoneal pseudomyxoma patients admitted to our hospital from 2002 to 2011 were included in this study. Their clinical data, including its postoperative complications and its prognosis-influencing factors were retrospectively analyzed. Results Of the 39 patients,17 (43%) developed complications after operation such as intestinal obstruction and intra-abdominal infection, 25 had recurrence with a median recurrence time of 12 months. The risk to develop complications after operation increased when the ECOG score was≥1 (P<0.05). No significant difference was observed in gender, age, operation time and hyperthermic intraperitoneal chemotherapy (HIPEC) among the patients (P > 0.05). Univariate and multivariate analyses showed that the peritoneal pseudomyxoma was pathologically typed as disseminated peritoneal adenomueinosis(DPAM). Operation in combination with HIPEC could delay its recurrence (P<0.05). Conclusion Postoperative complications of peritoneal pseudomyxoma should be prevented in patients with their ECOG score ≥1. Operation in combination with HIPEC can delay the recurrence of DPAM.